Sarepta Therapeutics, Inc.
$21.42
▲
4.97%
2026-04-21 09:36:00
www.sarepta.com
NMS: SRPT
Explore Sarepta Therapeutics, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$2.24 B
Current Price
$21.42
52W High / Low
$64.8 / $10.42
Stock P/E
—
Book Value
$10.87
Dividend Yield
—
ROCE
-29.18%
ROE
-53.47%
Face Value
—
EPS
$-7.13
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
835
Beta
0.28
Debt / Equity
91.14
Current Ratio
2.32
Quick Ratio
1.48
Forward P/E
6.96
Price / Sales
1.01
Enterprise Value
$2.32 B
EV / EBITDA
-3.79
EV / Revenue
1.06
Rating
Hold
Target Price
$21.7
EPS Forecast (FY)
—
Pros
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | Protalix BioTherapeutics, Inc. | $2.27 | — | $184.11 M | — | -9.85% | -14.44% | $3.19 / $1.32 | $0.6 |
| 2. | Coherus Oncology, Inc. | $1.99 | 1.76 | $295.28 M | — | -155.52% | -473.47% | $2.62 / $0.71 | $0.5 |
| 3. | Kiora Pharmaceuticals, Inc. | $2.52 | — | $9.96 M | — | -45.87% | -51.74% | $4.18 / $1.76 | $4.29 |
| 4. | Gain Therapeutics, Inc. | $2.12 | — | $89.98 M | — | -96.12% | -1.56% | $4.34 / $1.41 | $0.44 |
| 5. | Nurix Therapeutics, Inc. | $17.04 | — | $1.81 B | — | -47.48% | -61.4% | $22.5 / $8.2 | $4.65 |
| 6. | Nuvation Bio Inc. | $5.12 | — | $1.77 B | — | -41.57% | -53.18% | $9.75 / $1.57 | $0.88 |
| 7. | Olema Pharmaceuticals, Inc. | $16.58 | — | $1.47 B | — | -37.1% | -36.61% | $36.26 / $3.89 | $5.88 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 442.93 M | 399.36 M | 611.09 M | 744.86 M | 658.41 M | — |
| Operating Profit | -410.08 M | -62.88 M | 115.58 M | -300.39 M | 161.68 M | — |
| Net Profit | -282.85 M | -179.95 M | 196.89 M | -447.51 M | 159.05 M | — |
| EPS in Rs | -2.69 | -1.71 | 1.88 | -4.26 | 1.51 | — |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 2.2 B | 1.9 B | 1.24 B | 933.01 M |
| Operating Profit | -657.77 M | 218.08 M | -267.82 M | -536.2 M |
| Net Profit | -713.41 M | 235.24 M | -535.98 M | -703.49 M |
| EPS in Rs | -6.8 | 2.24 | -5.11 | -6.7 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 3.35 B | 3.96 B | 3.26 B | 3.13 B |
| Total Liabilities | 2.21 B | 2.44 B | 2.41 B | 2.74 B |
| Equity | 1.14 B | 1.53 B | 859.34 M | 384.95 M |
| Current Assets | 2.54 B | 3.07 B | 2.58 B | 2.56 B |
| Current Liabilities | 1.1 B | 731.68 M | 653.66 M | 619.6 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -205.48 M | -205.79 M | -500.99 M | -325.35 M |
| Investing CF | 69.64 M | 755.56 M | -165.8 M | -1.05 B |
| Financing CF | -168.34 M | 124.81 M | 125 M | 232.51 M |
| Free CF | -315.33 M | -352.74 M | -588.34 M | -357.6 M |
| Capex | -109.85 M | -146.96 M | -87.34 M | -32.25 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | 52.97% | 33.26% | — | — |
| Earnings Growth % | 143.89% | 23.81% | — | — |
| Profit Margin % | 12.37% | -43.11% | -75.4% | — |
| Operating Margin % | 11.47% | -21.54% | -57.47% | — |
| Gross Margin % | 83.22% | 87.91% | 85% | — |
| EBITDA Margin % | 16.66% | -36.49% | -63.76% | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
No stock split history available.